Clinical Trial Update: ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ACP-196 alone and with pembrolizumab in metastatic pancreatic cancer has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ACP-196 (acalabrutinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-01